Read further: Trial Study to Show Empagliflozin Outcomes In Patients of Chronic Heart Failure and Reduced Ejection Fraction—EMPEROR-Reduced
Most Recent Articles
Trial Study to Show Empagliflozin Outcomes In Patients of Chronic Heart Failure and Reduced Ejection Fraction—EMPEROR-Reduced
This study was carried out to check the efficacy of empagliflozin in heart failure patients. For this purpose sample of 1863 patients for empagliflozin dosage and 1867 for placebo treatment was randomized. Inclusion criteria were...
ACC’s Physician Fee Schedule Proposed Rule Calculator Now Updated for 2023
Just close to a month after the CMS released their 2023 Medicare Physician Fee Schedule proposed rule, the ACC in response has released a brand-new 2023 version of their Physician Fee Schedule Proposed Rule Calculator. The ACC...
Empagliflozin for HF-pEF and Its Effects on Patients Irrespective of Glycemic Status
Empagliflozin has been established as one of the possible key treatments for patients with heart failure with a preserved ejection fraction (HF-pEF). This study, on the other hand, attempts to address gaps in our understanding...
ACC Guidelines for Maternal Cardiovascular Care
The main purpose of the American College of Cardiology (ACC) is to change and recover the maternal health of cardiovascular patients through the shared decision of Doctors, the cardiovascular team, patients, and others.